Search Results 2171-2180 of 20178 for Receptor

  1. COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy - Mayo Clinic

    Have had prior treatment with regorafenib or any other (vascular endothelial growth factor receptor) VEGFR-targeting kinase inhibitor. Have had anti-cancer ...

  2. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

    Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy directed at any target. Any previous therapy that is targeted to B-cell maturation ...

  3. Dec. 4, 2012 Mayo Clinic IDs Genes That Predict Whether Trastuzumab Will Work for Breast Cancer Patients SAN ANTONIO, Texas —

    cycle, cell death, cell receptor signaling, and gene transcription. -next-. News Bureau. 200 First Street SW. Rochester, Minnesota 55905 http://www.mayoclinic ...

  4. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  5. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  6. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  7. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  8. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  9. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  10. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...